Short Interest in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Declines By 27.6%

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 13,100 shares, a decrease of 27.6% from the August 15th total of 18,100 shares. Based on an average daily volume of 7,300 shares, the days-to-cover ratio is currently 1.8 days. Approximately 1.0% of the company’s stock are short sold.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently raised its position in Creative Medical Technology stock. Aaron Wealth Advisors LLC increased its holdings in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) by 19.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,570 shares of the company’s stock after buying an additional 3,170 shares during the quarter. Aaron Wealth Advisors LLC owned 1.45% of Creative Medical Technology worth $75,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 1.42% of the stock is currently owned by hedge funds and other institutional investors.

Creative Medical Technology Stock Performance

CELZ stock traded down $0.14 during trading on Tuesday, reaching $3.25. 11,810 shares of the company traded hands, compared to its average volume of 77,236. The company has a market capitalization of $4.38 million, a price-to-earnings ratio of -0.88 and a beta of 2.11. The business has a 50 day simple moving average of $3.42 and a 200 day simple moving average of $4.21. Creative Medical Technology has a 12 month low of $2.90 and a 12 month high of $10.28.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings data on Friday, August 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.27). The firm had revenue of $0.01 million for the quarter. As a group, research analysts forecast that Creative Medical Technology will post -3.29 EPS for the current year.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.